High clinical costs with declining drug discovery success rates are causing productivity levels to fall in the global pharmaceuticals industry. The imminent patent expiry of several major blockbuster drugs and the related rise of cheaper generic alternatives is further exacerbating the situation. Despite this, the global pharmaceutical industry offers significant growth opportunity for participants that can build new strategic business models.